Intellia Therapeutics (NTLA) is a clinical-stage biotech firm working on CRISPR-based treatments that try to edit genes directly inside the body – basically aiming to fix diseases at their root with a one-time therapy. But NTLA stock has not exactly followed that story. Even with steady clinical progress, investors have stayed cautious. This is due to safety concerns circulating around gene editing, the idea of a permanent treatment still feels like a leap, competition from existing long-term drugs remaining strong, and NTLA is still burning cash with no commercial revenue yet. The stock remains nearly 95% below its 2021 peak.
But where the market hesitates, Cathie Wood leans in. Through her ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG), she recently picked up over 3.4 million shares worth around $43 million. She’s been adding steadily through 2026, so Intellia has become a meaningful position across her funds.
